Results 91 to 100 of about 25,279 (271)
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen +4 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Objective Long‐term memory deficits are often seen in patients with temporal lobe epilepsy (TLE). Recently, studies showed that patients with hippocampal sclerosis (HS) type 2, which presents with severe neuron loss in CA1 only, performed within the normal range. However, up to 30% of HS type 2 cases have memory deficits.
Henrique Cruz +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Findings are contradictory regarding changes in the incidence and prevalence of Parkinson's disease (PD) over time; data for other parkinsonian disorders are rare. Objectives To analyze temporal trends in the incidence and prevalence of eight parkinsonisms (PD, MSA, PSP, CBS, DLB, vascular parkinsonism, drug‐induced parkinsonism ...
Sacha E. Gandhi +7 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background and objectives Caregivers of progressive supranuclear palsy (PSP) patients frequently show significant distress. The Parkinsonism Carers quality of life (QoL) (PQoL Carer) is a valid tool evaluating the effect of PSP on caregivers' QoL.
Arianna Cappiello +73 more
wiley +1 more source
Characterizing Secondary and Atypical Parkinsonisms: Defining Features and Clinical Variability
NeurogliaParkinsonism is a clinical syndrome characterized by akinesia/bradykinesia, muscle rigidity, resting tremor, and postural instability. Within the group of parkinsonisms is Parkinson’s disease, also known as neurodegenerative parkinsonian syndrome.
Iraís Viveros-Martínez +8 more
doaj +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma +14 more
wiley +1 more source
Predictors of functional dependency in Parkinson’s disease [PDF]
, 2016 Financial disclosures/conflicts of interest: Dr Macleod was funded by a Clinical Academic Fellowship from the Chief Scientist Office of the Scottish Government and received grant funding from Parkinson’s UK, the Wellcome Trust, University of Aberdeen ...
Adler +33 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's Disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Structural brain changes, including atrophy in the midbrain, basal ganglia, and cortical regions such as the frontal and temporal lobes, are observed in advanced stages.
Suraiya Mangra +5 more
wiley +1 more source
Correlating familial Alzheimer’s disease gene mutations with clinical phenotype [PDF]
, 2010 Alzheimer’s disease (AD) causes devastating cognitive impairment and an intense research effort is currently devoted to developing improved treatments for it.
Rossor, M.N., Ryan, N.S.
core +1 more source
Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease [PDF]
, 2010 Objective To report the rare but distinct clinical and neuropathological phenotype of non-familial, rapidly progressive parkinsonism and dementia associated with frontotemporal lobar degeneration with motor neuron disease (FTLD-MND).
de Courten-Myers, Gabrielle M. +6 more
core +1 more source